Scarica l'app Stockscreener
1.07
4.46%
-0.05
Dopo l'orario di chiusura:
1.12
0.05
+4.67%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Unity Biotechnology Inc Borsa (UBX) Ultime notizie
Biotech company once valued at $700 million slashes entire workforce - KRON4
Bay Area biotech company lays off every single worker, including CEO - SFGATE
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
UNITY Biotechnology (UBX) Reports Promising 36-Week Results from ASPIRE Trial | UBX Stock News - GuruFocus
Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study - TipRanks
UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force - marketscreener.com
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates - The Manila Times
UNITY Biotechnology Announces Complete 36-Week Results from - GlobeNewswire
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of ... - Bluefield Daily Telegraph
UNITY's New DME Treatment Rivals Aflibercept in Phase 2b Trial, Company Explores Strategic Options - Stock Titan
UNITY Biotechnology to Present 36-Week Data from ASPIRE Phase 2B Study at ARVO 2025 Annual Meeting - Nasdaq
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting - GlobeNewswire
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
Chardan Capital Brokers Decrease Earnings Estimates for UBX - Defense World
Form 8-KCurrent report - ADVFN
HC Wainwright Issues Positive Outlook for UBX Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Chardan Capital Reaffirms “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Unity Biotechnology Reports Q1 2025 Financials and Study Updates - TipRanks
H.C. Wainwright maintains $4 target on Unity Biotech stock - Investing.com Australia
Unity Biotechnology (UBX) Reports $16.9M in Cash, Prepares for F - GuruFocus
H.C. Wainwright maintains $4 target on Unity Biotech stock By Investing.com - Investing.com Nigeria
UNITY Biotechnology (UBX) Shows Promise with Senolytic UBX1325 i - GuruFocus
UNITY Biotechnology Announces Publication in NEJM Evidence - GlobeNewswire
Revolutionary DME Drug Maintains Vision Improvement for 12 Months After Just One Dose, NEJM Study Shows - Stock Titan
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates | UBX Stock News - GuruFocus
UNITY Biotechnology Reports Q1 2025 Financial Results and ASPIRE Study Data on UBX1325 for Diabetic Macular Edema - Nasdaq
Unity Biotechnology, Inc. SEC 10-Q Report - TradingView
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
UNITY's Eye Disease Drug Matches Standard Treatment at 36 Weeks: Key Trial Results Revealed - Stock Titan
Unity Biotechnology stock hits 52-week low at $0.94 By Investing.com - Investing.com Canada
Unity Biotechnology stock hits 52-week low at $0.94 - Investing.com
Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock By Investing.com - Investing.com Australia
Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock - Investing.com
Unity Biotechnology Executives Sell Shares for Tax Obligations - TradingView
HC Wainwright Has Pessimistic Outlook of UBX FY2026 Earnings - The AM Reporter
What is HC Wainwright’s Estimate for UBX FY2026 Earnings? - Defense World
Unity Biotechnology (NASDAQ:UBX) Price Target Lowered to $4.00 at Chardan Capital - Defense World
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating - Investing.com Australia
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study - MSN
Unity Biotechnology price target lowered to $4 from $6 at Chardan - TipRanks
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating By Investing.com - Investing.com South Africa
UNITY Biotechnology tanks on mixed results for eye disease drug - The Pharma Letter
Mizuho maintains Unity Biotechnology Outperform rating By Investing.com - Investing.com South Africa
Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating - Marketscreener.com
Mizuho maintains Unity Biotechnology Outperform rating - Investing.com India
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $4.00 by Analysts at HC Wainwright - Defense World
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE - EIN News
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Sector Update: Health Care - TradingView
Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint - Marketscreener.com
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):